URL has been copied successfully!

URL has been copied successfully!

CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)

On: March 25, 2026

URL has been copied successfully!

Please follow us:

This post was originally published here

Previous Post:CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)

Next Post:Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts